首页> 外文期刊>Canadian Urological Association Journal >Hydrogen sulfide treatment ameliorates long-term renal dysfunction resulting from prolonged warm renal ischemia-reperfusion injury
【24h】

Hydrogen sulfide treatment ameliorates long-term renal dysfunction resulting from prolonged warm renal ischemia-reperfusion injury

机译:硫化氢处理改善了延长温暖肾缺血再灌注损伤的长期肾功能障碍

获取原文
           

摘要

Introduction: The incidence of renal cell carcinoma (RCC) continues to rise concurrently with the increased prevalence of end-stage renal disease worldwide. Treatment for small renal masses continues to be partial nephrectomy mostly involving the clamping of renal blood vessels. Although necessary, this technique results in warm renal ischemia and reperfusion injury (IRI) to the afflicted kidney. We have recently demonstrated that hydrogen sulfide (H2S), a novel endogenous gaseous molecule, protects against prolonged cold and short-term warm renal IRI. In the current study, we examined whether exogenous H2S has long-term protective effects against warm renal IRI associated with renal surgical procedures. Methods: Uni-nephrectomized Lewis rats underwent 1 hour of warm ischemia induced by clamping of the renal pelvis. Animals underwent either intraperitoneal treatment with phosphate buffered saline (PBS; IRI group) or PBS supplemented with 150 μM NaHS (H2S group), and were compared against Sham-operated rats. Results: H2S treatment improved long-term renal function as serum creatinine at day 7 was significantly decreased in the H2S group compared to IRI animals ( p 2S treatment decreased the expression of pro-inflammatory markers TLR-4, TNF-α, IFNγ, IL-2 and ICAM-1, increased the expression of pro-survival molecule Bcl-2 and decreased the expression of pro-apoptotic marker BID at postoperative day 1. H2S-treated kidneys also showed a significant decrease ( p 2S treatment improved long-term renal function and decreased long-term inflammation associated with warm IRI, and may offer a novel therapeutic approach to preventing warm IRI-induced renal injury associated with renal surgical procedures.
机译:介绍:肾细胞癌(RCC)的发病率随着全球终末期肾病的患病率增加而继续上升。小肾群的治疗仍然是部分肾切除术,主要是涉及肾脏血管的夹紧。虽然必要的是,这种技术导致温暖的肾缺血和再灌注损伤(IRI)给受贫磨的肾脏。我们最近证明了硫化氢(H 2 s),一种新的内源气态分子,可保护延长冷和短期温暖肾IRI。在目前的研究中,我们检查了外源性H 2 对与肾外科手术相关的温暖肾IRI具有长期保护作用。方法:通过夹紧肾盂夹紧诱导1小时的温暖缺血的单肾切除术大鼠。通过磷酸盐缓冲盐水(PBS; IRI基团)或补充有150μMNaHs(H 2 S组)的PBS进行腹膜内处理,并与假手术大鼠进行比较。结果:H 2 S治疗改善了与IRI动物相比,H 2 S组在第7天的血清肌酐的长期肾功能显着降低(P 2 S治疗降低了促炎标记物TLR-4,TNF-α,IFNγ,IL-2和ICAM-1的表达,增加了促生物质分子Bcl-2的表达并降低了促凋亡标记的表达在术后第1天竞标1. H 2 S-prequed肾脏还显示出显着的降低(p 2 S治疗,改善了长期肾功能,并且与温暖的IRI相关的长期炎症降低,并可提供一种新的治疗方法,以防止温暖的IRI诱导与肾外科手术相关的肾损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号